ETRACS 2x Leveraged IFED Invest with the Fed TR Index ETN (ARCA: FEDL)

ETRACS 2x Leveraged IFED Invest with the Fed TR Index ETN (ARCA:FEDL), Trade Ideas

ETRACS 2x Leveraged IFED Invest with the Fed TR Index ETN

Oppenheimer analyst Jay Olson maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Outperform and lowers the price target from $92 to $84.

News

Price Target

Analyst Ratings

INCY

Oppenheimer Maintains Outperform on Incyte, Lowers Price Target to $84

The Company this week will make its first sale and shipment of oil produced at the McCool Ranch Field in Monterey County, California. The Company will ship approximately 2,100 barrels of oil, which were produced primarily from the HH-1 well that was brought back online in late February of 2024. Net of&nbsp;16.67%&nbsp;royalties and oil trucking costs, the&nbsp;80%&nbsp;net revenues to TPET from this sale are expected to be approximately&nbsp;$105,000.

TPET

Trio Petroleum Begins Oil Sales From California Assets

Benchmark analyst Matthew Harrigan maintains Spotify Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) with a Buy and raises the price target from $325 to $375.

SPOT

Benchmark Maintains Buy on Spotify Technology, Raises Price Target to $375

TD And ApplyBoard Announce A New Collaboration That Will Support International Students On Their Journey To Study In Canada

Oppenheimer analyst Colin Rusch maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Outperform and raises the price target from $133 to $134.

ENPH

Oppenheimer Maintains Outperform on Enphase Energy, Raises Price Target to $134

<a href="https://www.curevac.com/en/curevac-announces-start-of-combined-phase-1-2-study-in-avian-influenza-h5n1-development-in-collaboration-with-gsk/" title="https://www.curevac.com/en/curevac-announces-start-of-combined-phase-1-2-study-in-avian-influenza-h5n1-development-in-collaboration-with-gsk/">https://www.curevac.com/en/curevac-announces-start-of-combined-phase-1-2-study-in-avian-influenza-h5n1-development-in-collaboration-with-gsk/</a>

Biotech

Health Care

General

CVAC

CureVac Has Started The Phase 1 Part Of A Combined Phase 1/2 Study Of An Investigational Influenza A (H5N1) Pre-Pandemic Vaccine Candidate Developed In Collaboration With GSK, H5N1 Is An Avian Influenza Virus

Contracts

RBBN

Ribbon Communications Announced Plans For A Major Network Modernization Program With Verizon To Retire Legacy TDM Switching Platforms And Replace Their Function With Modern Cloud-based Technologies

Management

Village Farms International Names Ann Gillin Lefever As Chief Operating Officer

AUGX

Augmedix Announced The General Availability Of Augmedix Go For Emergency Departments (EDs), Marking The Launch Of The Industry's First Fully-automated, Generative Ai Powered Medical Documentation Product For EDs Across The Country

Benchmark analyst Todd Brooks maintains Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) with a Buy and lowers the price target from $4 to $3.

NDLS

Benchmark Maintains Buy on Noodles, Lowers Price Target to $3

Large Cap

CureVac And GSK Will End The Pandemic Preparedness Agreement Jointly Concluded With The Federal Republic Of Germany In April 2022, After Consultation With The German Federal Ministry Of Health

CureVac Is Implementing In 2024 An Organizational Redesign To Streamline Structures And Reduce Operating Costs. The Program Was Initiated With A "Voluntary Leaver" Program, To Reduce 150 Position

ASLN

ASLAN Pharmaceuticals Disclosed Late Breaking Abstract On Eblasakimab In COPD Accepted For Presentation At The American Thoracic Society International Conference

Net loss of approximately&nbsp;$36&nbsp;million, primarily driven by a&nbsp;$63&nbsp;million&nbsp;expense associated with legacy litigation.&nbsp;Cash and cash equivalents of approximately&nbsp;$423&nbsp;million.
Organic revenue CAGR (2024-2027)&nbsp;of approximately&nbsp;10%, to approximately&nbsp;$15.5 billion&nbsp;to&nbsp;$16.0 billion&nbsp;of revenue.&nbsp;Adjusted diluted EPS CAGR (2024-2027)&nbsp;of more than&nbsp;15%.

Guidance

GXO Reports Preliminary Q1 2024 Results, Revenue Of $2.5B, Est $2.375B; Updates Its 2027 Financial Targets

WIIM

SLAB

Silicon Laboratories shares are trading higher after the company reported better-than-expected Q1 results and issued Q2 guidance.

CureVac's Cash And Cash Equivalents Position Of €402.5M As Of December 31, 2023 Is Expected To Provide Cash Runway Into Q4 2025

TransAlta Announced That The Combined 300 MW White Rock East And White Rock West Wind Facilities, Located In Caddo County, Oklahoma, Have Achieved Commercial Operation

Earnings

Earnings Misses

CureVac Q4 Sales €22.600M Miss €33.744M Estimate

Mr. Cooper Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NASDAQ">COOP</a>) reported quarterly earnings of $2.28 per share which beat the analyst consensus estimate of $2.09 by 9.09 percent. The company reported quarterly sales of $564.000 million which beat the analyst consensus estimate of $497.060 million by 13.47 percent. This is a 70.91 percent increase over sales of $330.000 million the same period last year.

Earnings Beats

COOP

Mr. Cooper Gr Q1 2024 Adj EPS $2.28 Beats $2.09 Estimate, Sales $564.000M Beat $497.060M Estimate

&quot;With the year beginning largely as expected, we continue to anticipate that 2024 adjusted earnings per share will be in the range of&nbsp;$4.00&nbsp;to&nbsp;$4.25&nbsp;per share,&quot; said Allman. &quot;Through our ongoing investments in our market leading brands, innovation, and service and our disciplined capital allocation strategy, we are confident in Masco&#39;s ability to continue to deliver long-term shareholder value.&quot;

Masco Continues To Expects FY24 Adj. EPS Between $4.00-$4.25 Vs. $4.13 Consensus

ZC SP ETN REDEEM 15/09/2061 USD 25 - Ser B